Sickweather Adds Healthcare, Pharma and Informatics Leader to Board

A veteran of the healthcare, pharmaceutical and informatics industries, Laurel Edelman joined the Sickweather Board of Directors on November 1, 2018. The company will leverage Edelman’s extensive business development experience to advance Sickweather’s mission to provide the most accurate, predictive and meaningful sickness forecast in the world and to help guide the company’s rapid growth. Edelman also serves as Sickweather’s Chief Revenue Officer.

As the world’s first real-time map of human health, Sickweather collects and processes millions of illness reports each month to deliver a street-level view of what’s going around in a specific area. Flu, colds, allergies and a variety of other illnesses are tracked daily across the country and around the world.

Edelman is credited for developing strategic blueprints to guide leading life sciences companies in proactively developing business practices, policies, and technology solutions to drive more predictable revenue. She has also been instrumental in expanding the use of novel healthcare data assets in public health, including influenza surveillance for a key federal agency.

“We’re excited to have someone of Laurel’s caliber join our board,” said Graham Dodge, Sickweather CEO and President. “Her industry knowledge and experience developing businesses is the perfect fit for the next phase of our development. We’re also incredibly fortunate to have one of the leading women in the industry casting the vision for our company operations and culture.”

Most recently Senior Director for Business Development at ICON Government and Public Health Solutions, Edelman also led business development for IMS Government Solutions (now IQVIA, NYSE: IQV) leveraging healthcare data and informatics to assist Government decision makers in civilian healthcare policy, research, and operations. She has also held key positions with AstraZeneca, Publicis Healthcare, Symphony Health Solutions and pharma start-up Requis Pharmaceuticals.